STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma

Cancer Research

Volumn 75, Issue 20, 2015, Pages 4302-4311

  Lau, Jasmine ^a,b,d   Ilkhanizadeh, Shirin ^a,b   Wang, Susan ^a,b,c   Miroshnikova, Yekaterina A ^a   Salvatierra, Nicolas A ^a,b   Wong, Robyn A ^a,b   Schmidt, Christin ^a,b   Weaver, Valerie M ^a,b   Weiss, William A ^a,b   Persson, Anders I ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AGENCY FOR SCIENCE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; JANUS KINASE 2; RUXOLITINIB; STAT3 PROTEIN; BIOLOGICAL MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CULTURE; CELL INVASION; CELL MOTILITY; CELL TRANSFORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; ENZYME INHIBITION; GENETIC ENGINEERING; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PRONEURAL TO MESENCHYMAL TRANSITION; SIGNAL TRANSDUCTION; SURVIVAL RATE; ALLOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER STEM CELL; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; RADIATION; RADIATION RESPONSE;

ALLOGRAFTS; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; JANUS KINASE 2; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; RADIATION; STAT3 TRANSCRIPTION FACTOR;

EID: 84945975205     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3331     Document Type: Article

References (33)

1. Walker MD, AlexanderE Jr, Hunt WE, MacCarty CS, MahaleyMS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49: 333-43.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507.
4. DeAngelis LM. Chemotherapy for brain tumors-anew beginning.NEngl J Med 2005;352:1036-8.
5. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
6. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glio-blastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
7. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW, Konermann C, et al. Hotspot Mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012; 22:425-37.
8. Cooper LAD, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS ONE 2010;5: e12548.
9. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS ONE. 2014;9:e91216.
10. Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-kB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24: 331-46.
11. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482-90.
12. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21-35.
13. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK. Integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizu-mab-resistant glioblastoma. Cancer Res 2013;73:3145-54.
14. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
15. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438-49.
16. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2009;463:318-25.
17. Bhat KPL, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, et al. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev 2011; 25:2594-609.
18. Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, et al. Mesen-chymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest 2013;123:405-17.
19. Cooper LAD, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol 2012; 180:2108-19.
20. Halliday J, Helmy K, Pattwell SS, Pitter KL, LaPlant Q, Ozawa T, et al. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift.Proc Natl Acad Sci USA 2014;111:5248-53.
21. Mao P, Joshi K, Li J, Kim S-H, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci USA 2013; 110:8644-9.
22. Weiss WA, Burns MJ, Hackett C, Aldape K, Hill JR, Kuriyama H, et al. Genetic determinants of malignancy in a mouse model for oligodendro-glioma. Cancer Res 2003;63:1589-95.
23. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, et al. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001;61:3826-36.
24. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell 2010;18:669-82.
25. Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, Guha A. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 2005;167:859-67.
26. Hughes EG, Kang SH, Fukaya M, Bergles DE. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat Neurosci 2013;16:668-76.
27. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem. Cells 2009;27:2383-92.
28. Kim E, Kim M, Woo D-H, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013;23: 839-52.
29. Schindler C, Darnell JE. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995;64:621-51.
30. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363: 1117-27.
31. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors. Cancer Cell 2009;16:487-97.
32. Plimack ER, LoRusso PM, McCoon P, Tang W, Krebs AD, Curt G, et al. AZD1480: A phase i study of a novel JAK2 inhibitor in solid tumors. Oncologist 2013;18:819-20.
33. Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev 2012;64:520-39.